Biomarkers in Asthma. A Real Hope to Better Manage Asthma

Clinics in Chest Medicine

Volumn 33, Issue 3, 2012, Pages 459-471

  Erzurum, Serpil C ^a   Gaston, Benjamin M ^b  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Asthma; Asthma management; Biomarkers

Indexed keywords

3 BROMOTYROSINE; ARGINASE; ARGININE; BIOLOGICAL MARKER; LEUKOTRIENE E4; LIPOXIN; METHYLARGININE DERIVATIVE; NITRIC OXIDE; S NITROSOGLUTATHIONE; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR RUNX2; TYROSINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ASTHMA; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ACTIVITY; EOSINOPHIL COUNT; HUMAN; LIPID OXIDATION; MANAGED CARE; NONHUMAN; OBESITY; PATHOGENESIS; PATIENT CARE; PATIENT IDENTIFICATION; PH MEASUREMENT; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TH2 CELL;

EID: 84865545734     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2012.06.007     Document Type: Review

References (139)

1. Yawn B.P., Brenneman S.K., Allen-Ramey F.C., et al. Assessment of asthma severity and asthma control in children. Pediatrics 2006, 118:322-329.
2. National Heart Lung and Blood Institute. Expert panel report 3: guidelines for the diagnosis and management of asthma full report. Available at: Accessed July 2, 2012. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf.
3. Wenzel S., Holgate S.T. The mouse trap: it still yields few answers in asthma. Am J Respir Crit Care Med 2006, 174:1173-1176. [discussion: 6-8].
4. Masoli M., Fabian D., Holt S., et al. The global burden of asthma: executive summary of the GINA dissemination Committee report. Allergy 2004, 59:469-478.
5. Busse W.W., Banks-Schlegel S., Wenzel S.E. Pathophysiology of severe asthma. J Allergy Clin Immunol 2000, 106:1033-1042.
6. Moore W.C., Bleecker E.R., Curran-Everett D., et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007, 119:405-413.
7. Paull K., Covar R., Jain N., et al. Do NHLBI lung function criteria apply to children? A cross-sectional evaluation of childhood asthma at National Jewish Medical and Research Center, 1999-2002. Pediatr Pulmonol 2005, 39:311-317.
8. ATS Workshop Proceedings: exhaled nitric oxide and nitric oxide oxidative metabolism in exhaled breath condensate: executive summary. Am J Respir Crit Care Med 2006, 173:811-813.
9. Wenzel S.E. Asthma: defining of the persistent adult phenotypes. Lancet 2006, 368:804-813.
10. Gaston B. The biochemistry of asthma. Biochim Biophys Acta 2011, 1810:1017-1024.
11. Anderson G.P. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008, 372:1107-1119.
12. Leckie M.J., ten Brinke A., Khan J., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 356:2144-2148.
13. Pavord I.D., Shaw D.E., Gibson P.G., et al. Inflammometry to assess airway diseases. Lancet 2008, 372:1017-1019.
14. Meyers D.A., Postma D.S., Stine O.C., et al. Genome screen for asthma and bronchial hyperresponsiveness: interactions with passive smoke exposure. J Allergy Clin Immunol 2005, 115:1169-1175.
15. Moore W.C., Meyers D.A., Wenzel S.E., et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010, 181:315-323.
16. Fitzpatrick A.M., Teague W.G., Meyers D.A., et al. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol 2010, 127:382-389. e1-13.
17. Woodruff P.G., Khashayar R., Lazarus S.C., et al. Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. J Allergy Clin Immunol 2001, 108:753-758.
18. Polosa R., Renaud L., Cacciola R., et al. Sputum eosinophilia is more closely associated with airway responsiveness to bradykinin than methacholine in asthma. Eur Respir J 1998, 12:551-556.
19. Louis R., Lau L.C., Bron A.O., et al. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 2000, 161:9-16.
20. Covar R.A., Spahn J.D., Martin R.J., et al. Safety and application of induced sputum analysis in childhood asthma. J Allergy Clin Immunol 2004, 114:575-582.
21. Gibson P.G. Use of induced sputum to examine airway inflammation in childhood asthma. J Allergy Clin Immunol 1998, 102:S100-101.
22. Berry M., Morgan A., Shaw D.E., et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 2007, 62:1043-1049.
23. Hastie A.T., Moore W.C., Meyers D.A., et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol 2010, 125:1028-1036. e13.
24. Woodruff P.G., Modrek B., Choy D.F., et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009, 180:388-395.
25. Corren J., Lemanske R.F., Hanania N.A., et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011, 365:1088-1098.
26. MacPherson J.C., Comhair S.A., Erzurum S.C., et al. Eosinophils are a major source of nitric oxide-derived oxidants in severe asthma: characterization of pathways available to eosinophils for generating reactive nitrogen species. J Immunol 2001, 166:5763-5772.
27. Aldridge R.E., Chan T., van Dalen C.J., et al. Eosinophil peroxidase produces hypobromous acid in the airways of stable asthmatics. Free Radic Biol Med 2002, 33:847-856.
28. Erpenbeck V.J., Hohlfeld J.M., Petschallies J., et al. Local release of eosinophil peroxidase following segmental allergen provocation in asthma. Clin Exp Allergy 2003, 33:331-336.
29. Wu W., Chen Y., d'Avignon A., et al. 3-Bromotyrosine and 3,5-dibromotyrosine are major products of protein oxidation by eosinophil peroxidase: potential markers for eosinophil-dependent tissue injury in vivo. Biochemistry 1999, 38:3538-3548.
30. Mita H., Higashi N., Taniguchi M., et al. Urinary 3-bromotyrosine and 3-chlorotyrosine concentrations in asthmatic patients: lack of increase in 3-bromotyrosine concentration in urine and plasma proteins in aspirin-induced asthma after intravenous aspirin challenge. Clin Exp Allergy 2004, 34:931-938.
31. Wedes S.H., Wu W., Comhair S.A., et al. Urinary bromotyrosine measures asthma control and predicts asthma exacerbations in children. J Pediatr 2011, 159. 248-255. e1.
32. Gaston B., Sears S., Woods J., et al. Bronchodilator S-nitrosothiol deficiency in asthmatic respiratory failure. Lancet 1998, 351:1317-1319.
33. Que L.G., Liu L., Yan Y., et al. Protection from experimental asthma by an endogenous bronchodilator. Science 2005, 308:1618-1621.
34. Que L.G., Yang Z., Stamler J.S., et al. S-nitrosoglutathione reductase: an important regulator in human asthma. Am J Respir Crit Care Med 2009, 180:226-231.
35. Gaston B., Reilly J., Drazen J.M., et al. Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways. Proc Natl Acad Sci U S A 1993, 90:10957-10961.
36. Gaston B., Kelly R., Urban P., et al. Buffering airway acid decreases exhaled nitric oxide in asthma. J Allergy Clin Immunol 2006, 118:817-822.
37. Evangelista A.M., Rao V.S., Filo A.R., et al. Direct regulation of striated muscle myosins by nitric oxide and endogenous nitrosothiols. PloS One 2010, 5:e11209.
38. Whalen E.J., Foster M.W., Matsumoto A., et al. Regulation of beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2. Cell 2007, 129:511-522.
39. Fang K., Johns R., Macdonald T., et al. S-nitrosoglutathione breakdown prevents airway smooth muscle relaxation in the guinea pig. Am J Physiol 2000, 279:L716-L721.
40. Marozkina N.V., Wei C., Yemen S., et al. S-nitrosoglutathione reductase in human lung cancer. Am J Respir Cell Mol Biol 2011, 46:63-70.
41. Jensen D.E., Belka G.K., Du Bois G.C. S-nitrosoglutathione is a substrate for rat alcohol dehydrogenase class III isoenzyme. Biochem J 1998, 331(Pt 2):659-668.
42. Greenwald R., Fitzpatrick A.M., Gaston B., et al. Breath formate is a marker of airway S-nitrosothiol depletion in severe asthma. PloS One 2010, 5:e11919.
43. Snyder A.H., McPherson M.E., Hunt J.F., et al. Acute effects of aerosolized S-nitrosoglutathione in cystic fibrosis. Am J Respir Crit Care Med 2002, 165:922-926.
44. Shin H.W., Shelley D.A., Henderson E.M., et al. Airway nitric oxide release is reduced after PBS inhalation in asthma. J Appl Physiol 2007, 102:1028-1033.
45. Caramori G., Papi A. Oxidants and asthma. Thorax 2004, 59:170-173.
46. Mak J.C., Chan-Yeung M.M. Reactive oxidant species in asthma. Curr Opin Pulm Med 2006, 12:7-11.
47. Andreadis A.A., Hazen S.L., Comhair S.A., et al. Oxidative and nitrosative events in asthma. Free Radic Biol Med 2003, 35:213-225.
48. Comhair S.A., Erzurum S.C. Redox control of asthma: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 2010, 12:93-124.
49. Dworski R., Murray J.J., Roberts L.J., et al. Allergen-induced synthesis of F(2)-isoprostanes in atopic asthmatics. Evidence for oxidant stress. Am J Respir Crit Care Med 1999, 160:1947-1951.
50. Morrow J.D., Roberts L.J. The isoprostanes: their role as an index of oxidant stress status in human pulmonary disease. Am J Respir Crit Care Med 2002, 166:S25-S30.
51. Wood L.G., Gibson P.G., Garg M.L. Biomarkers of lipid peroxidation, airway inflammation and asthma. Eur Respir J 2003, 21:177-186.
52. Tse S.M., Tantisira K., Weiss S.T. The pharmacogenetics and pharmacogenomics of asthma therapy. Pharmacogen J 2011, 11:383-392.
53. Dworski R., Sheller J.R. Urinary mediators and asthma. Clin Exp Allergy 1998, 28:1309-1312.
54. Heffner J.E., Repine J.E. Pulmonary strategies of antioxidant defense. Am Rev Respir Dis 1989, 140:531-554.
55. De Raeve H.R., Thunnissen F.B., Kaneko F.T., et al. Decreased Cu, Zn-SOD activity in asthmatic airway epithelium: correction by inhaled corticosteroid in vivo. Am J Physiol 1997, 272:L148-L154.
56. Comhair S.A., Bhathena P.R., Dweik R.A., et al. Rapid loss of superoxide dismutase activity during antigen-induced asthmatic response. Lancet 2000, 355:624.
57. Comhair S.A., Erzurum S.C. Antioxidant responses to oxidant-mediated lung diseases. Am J Physiol 2002, 283:L246-L255.
58. Comhair S.A., Gaston B.M., Ricci K.S., et al. Detrimental effects of environmental tobacco smoke in relation to asthma severity. PloS One 2011, 6:e18574.
59. Comhair S.A., Ricci K.S., Arroliga M., et al. Correlation of systemic superoxide dismutase deficiency to airflow obstruction in asthma. Am J Respir Crit Care Med 2005, 172:306-313.
60. Comhair S.A., Xu W., Ghosh S., et al. Superoxide dismutase inactivation in pathophysiology of asthmatic airway remodeling and reactivity. Am J Pathol 2005, 166:663-674.
61. Larsen G.L., White C.W., Takeda K., et al. Mice that overexpress Cu/Zn superoxide dismutase are resistant to allergen-induced changes in airway control. Am J Physiol 2000, 279:L350-L359.
62. Ghosh S., Janocha A.J., Aronica M.A., et al. Nitrotyrosine proteome survey in asthma identifies oxidative mechanism of catalase inactivation. J Immunol 2006, 176:5587-5597.
63. Hunt J.F., Erwin E., Palmer L., et al. Expression and activity of pH-regulatory glutaminase in the human airway epithelium. Am J Respir Crit Care Med 2002, 165:101-107.
64. Carraro S., Doherty J., Zaman K., et al. S-nitrosothiols regulate cell-surface pH buffering by airway epithelial cells during the human immune response to rhinovirus. Am J Physiol 2006, 290:L827-L832.
65. Hunt J.F., Fang K., Malik R., et al. Endogenous airway acidification. Implications for asthma pathophysiology. Am J Respir Crit Care Med 2000, 161:694-699.
66. Liu L., Teague W.G., Erzurum S., et al. Determinants of exhaled breath condensate pH in a large population with asthma. Chest 2011, 139:328-336.
67. Barbato A., Turato G., Baraldo S., et al. Epithelial damage and angiogenesis in the airways of children with asthma. Am J Respir Crit Care Med 2006, 174:975-981.
68. Hashimoto M., Tanaka H., Abe S. Quantitative analysis of bronchial wall vascularity in the medium and small airways of patients with asthma and COPD. Chest 2005, 127:965-972.
69. Asosingh K., Swaidani S., Aronica M., et al. Th1- and Th2-dependent endothelial progenitor cell recruitment and angiogenic switch in asthma. J Immunol 2007, 178:6482-6494.
70. Jackson J.R., Seed M.P., Kircher C.H., et al. The codependence of angiogenesis and chronic inflammation. Faseb J 1997, 11:457-465.
71. Chetta A., Zanini A., Foresi A., et al. Vascular endothelial growth factor up-regulation and bronchial wall remodelling in asthma. Clin Exp Allergy 2005, 35:1437-1442.
72. Psarras S., Volonaki E., Skevaki C.L., et al. Vascular endothelial growth factor-mediated induction of angiogenesis by human rhinoviruses. J Allergy Clin Immunol 2006, 117:291-297.
73. Avdalovic M.V., Putney L.F., Schelegle E.S., et al. Vascular remodeling is airway generation-specific in a primate model of chronic asthma. Am J Respir Crit Care Med 2006, 174:1069-1076.
74. Lee C.G., Link H., Baluk P., et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nature Med 2004, 10:1095-1103.
75. Puxeddu I., Alian A., Piliponsky A.M., et al. Human peripheral blood eosinophils induce angiogenesis. Int J Biochem Cell Biol 2005, 37:628-636.
76. Ribatti D., Crivellato E., Roccaro A.M., et al. Mast cell contribution to angiogenesis related to tumour progression. Clin Exp Allergy 2004, 34:1660-1664.
77. Prater D.N., Case J., Ingram D.A., et al. Working hypothesis to redefine endothelial progenitor cells. Leukemia 2007, 21:1141-1149.
78. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967.
79. Kharitonov S.A., Yates D., Robbins R.A., et al. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994, 343:133-135.
80. Ricciardolo F.L., Gaston B., Hunt J. Acid stress in the pathology of asthma. J Allergy Clin Immunol 2004, 113:610-619.
81. Smith A.D., Cowan J.O., Brassett K.P., et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005, 352:2163-2173.
82. Dinakar C. Exhaled nitric oxide in pediatric asthma. Curr Allergy Asthma Rep 2009, 9:30-37.
83. Nordvall S.L., Janson C., Kalm-Stephens P., et al. Exhaled nitric oxide in a population-based study of asthma and allergy in schoolchildren. Allergy 2005, 60:469-475.
84. Silkoff P.E., Carlson M., Bourke T., et al. The Aerocrine exhaled nitric oxide monitoring system NIOX is cleared by the US Food and Drug Administration for monitoring therapy in asthma. J Allergy Clin Immunol 2004, 114:1241-1256.
85. Dweik R.A., Sorkness R.L., Wenzel S., et al. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. Am J Respir Crit Care Med 2010, 181:1033-1041.
86. Guo F.H., Comhair S.A., Zheng S., et al. Molecular mechanisms of increased nitric oxide (NO) in asthma: evidence for transcriptional and post-translational regulation of NO synthesis. J Immunol 2000, 164:5970-5980.
87. Guo F.H., Erzurum S.C. Characterization of inducible nitric oxide synthase expression in human airway epithelium. Environ Health Perspect 1998, 106(Suppl 5):1119-1124.
88. Guo F.H., Uetani K., Haque S.J., et al. Interferon gamma and interleukin 4 stimulate prolonged expression of inducible nitric oxide synthase in human airway epithelium through synthesis of soluble mediators. J Clin Invest 1997, 100:829-838.
89. Shaw D.E., Berry M.A., Thomas M., et al. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med 2007, 176:231-237.
90. Szefler S.J., Mitchell H., Sorkness C.A., et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet 2008, 372:1065-1072.
91. Khatri S.B., Hammel J., Kavuru M.S., et al. Temporal association of nitric oxide levels and airflow in asthma after whole lung allergen challenge. J Appl Physiol 2003, 95:436-440. [discussion: 5].
92. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med 2000, 162:2341-2351.
93. Wedes S.H., Khatri S.B., Zhang R., et al. Noninvasive markers of airway inflammation in asthma. Clin Transl Sci 2009, 2:112-117.
94. Nelson B.V., Sears S., Woods J., et al. Expired nitric oxide as a marker for childhood asthma. J Pediatr 1997, 130:423-427.
95. Ceylan E., Aksoy N., Gencer M., et al. Evaluation of oxidative-antioxidative status and the L-arginine-nitric oxide pathway in asthmatic patients. Respir Med 2005, 99:871-876.
96. Li H., Romieu I., Sienra-Monge J.J., et al. Genetic polymorphisms in arginase I and II and childhood asthma and atopy. J Allergy Clin Immunol 2006, 117:119-126.
97. Morris C.R., Poljakovic M., Lavrisha L., et al. Decreased arginine bioavailability and increased serum arginase activity in asthma. Am J Respir Crit Care Med 2004, 170:148-153.
98. Lara A., Khatri S.B., Wang Z., et al. Alterations of the arginine metabolome in asthma. Am J Respir Crit Care Med 2008, 178:673-681.
99. Zimmermann N., King N.E., Laporte J., et al. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest 2003, 111:1863-1874.
100. Zimmermann N., Rothenberg M.E. The arginine-arginase balance in asthma and lung inflammation. Eur J Pharmacol 2006, 533:253-262.
101. Maarsingh H., Leusink J., Bos I.S., et al. Arginase strongly impairs neuronal nitric oxide-mediated airway smooth muscle relaxation in allergic asthma. Respir Res 2006, 7:6.
102. King N.E., Rothenberg M.E., Zimmermann N. Arginine in asthma and lung inflammation. J Nutr 2004, 134:2830S-2836S. [discussion: 53S].
103. Corraliza I.M., Soler G., Eichmann K., et al. Arginase induction by suppressors of nitric oxide synthesis (IL-4, IL-10 and PGE2) in murine bone-marrow-derived macrophages. Biochem Biophys Res Commun 1995, 206:667-673.
104. Modolell M., Corraliza I.M., Link F., et al. Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by TH1 and TH2 cytokines. Eur J Immunol 1995, 25:1101-1104.
105. Mistry S.K., Zheng M., Rouse B.T., et al. Induction of arginases I and II in cornea during herpes simplex virus infection. Virus Res 2001, 73:177-182.
106. Ito A., Tsao P.S., Adimoolam S., et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999, 99:3092-3095.
107. Cohen L., E X., Tarsi J., et al. Epithelial cell proliferation contributes to airway remodeling in severe asthma. Am J Respir Crit Care Med 2007, 176:138-145.
108. Li H., Meininger C.J., Hawker J.R., et al. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab 2001, 280:E75-E82.
109. Janne J., Alhonen L., Leinonen P. Polyamines: from molecular biology to clinical applications. Ann Med 1991, 23:241-259.
110. Albina J.E., Abate J.A., Mastrofrancesco B. Role of ornithine as a proline precursor in healing wounds. J Surg Res 1993, 55:97-102.
111. Kershenobich D., Fierro F.J., Rojkind M. The relationship between the free pool of proline and collagen content in human liver cirrhosis. J Clin Invest 1970, 49:2246-2249.
112. Haworth O., Levy B.D. Endogenous lipid mediators in the resolution of airway inflammation. Eur Respir J 2007, 30:980-992.
113. O'Byrne P.M., Israel E., Drazen J.M. Antileukotrienes in the treatment of asthma. Ann Intern Med 1997, 127:472-480.
114. Kalayci O., Birben E., Sackesen C., et al. ALOX5 promoter genotype, asthma severity and LTC production by eosinophils. Allergy 2006, 61:97-103.
115. Montuschi P., Mondino C., Koch P., et al. Effects of montelukast treatment and withdrawal on fractional exhaled nitric oxide and lung function in children with asthma. Chest 2007, 132:1876-1881.
116. Rabinovitch N., Graber N.J., Chinchilli V.M., et al. Urinary leukotriene E4/exhaled nitric oxide ratio and montelukast response in childhood asthma. J Allergy Clin Immunol 2010, 126. 545-551. e1-4.
117. Daffern P.J., Muilenburg D., Hugli T.E., et al. Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses. J Allergy Clin Immunol 1999, 104:559-564.
118. O'Shaughnessy K.M., Wellings R., Gillies B., et al. Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion. Am Rev Respir Dis 1993, 147:1472-1476.
119. O'Sullivan S., Roquet A., Dahlen B., et al. Urinary excretion of inflammatory mediators during allergen-induced early and late phase asthmatic reactions. Clin Exp Allergy 1998, 28:1332-1339.
120. Green S.A., Malice M.P., Tanaka W., et al. Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation. Thorax 2004, 59:100-104.
121. Liu M.C., Dube L.M., Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. J Allergy Clin Immunol 1996, 98:859-871.
122. Wenzel S.E., Trudeau J.B., Kaminsky D.A., et al. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med 1995, 152:897-905.
123. Pavord I.D., Ward R., Woltmann G., et al. Induced sputum eicosanoid concentrations in asthma. Am J Respir Crit Care Med 1999, 160:1905-1909.
124. Miranda C., Busacker A., Balzar S., et al. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004, 113:101-108.
125. Levy B.D. Lipoxins and lipoxin analogs in asthma. Prostaglandins Leukot Essent Fatty Acids 2005, 73:231-237.
126. Haworth O., Cernadas M., Yang R., et al. Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol 2008, 9:873-879.
127. Planaguma A., Kazani S., Marigowda G., et al. Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am J Respir Crit Care Med 2008, 178:574-582.
128. Levy B.D., Bonnans C., Silverman E.S., et al. Diminished lipoxin biosynthesis in severe asthma. Am J Respir Crit Care Med 2005, 172:824-830.
129. Levy B.D., Kohli P., Gotlinger K., et al. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol 2007, 178:496-502.
130. Farha S., Asosingh K., Laskowski D., et al. Effects of the menstrual cycle on lung function variables in women with asthma. Am J Respir Crit Care Med 2009, 180:304-310.
131. Tantisira K.G., Colvin R., Tonascia J., et al. Airway responsiveness in mild to moderate childhood asthma: sex influences on the natural history. Am J Respir Crit Care Med 2008, 178:325-331.
132. Holguin F., Bleecker E.R., Busse W.W., et al. Obesity and asthma: an association modified by age of asthma onset. J Allergy Clin Immunol 2011, 127:1486-1493. e2.
133. Holguin F., Fitzpatrick A. Obesity, asthma, and oxidative stress. J Appl Physiol 2010, 108:754-759.
134. Chupp G.L., Lee C.G., Jarjour N., et al. A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med 2007, 357:2016-2027.
135. Sorkness R.L., Bleecker E.R., Busse W.W., et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol 2008, 104:394-403.
136. Little S.A., Sproule M.W., Cowan M.D., et al. High resolution computed tomographic assessment of airway wall thickness in chronic asthma: reproducibility and relationship with lung function and severity. Thorax 2002, 57:247-253.
137. Mitsunobu F., Ashida K., Hosaki Y., et al. Decreased computed tomographic lung density during exacerbation of asthma. Eur Respir J 2003, 22:106-112.
138. Busacker A., Newell J.D., Keefe T., et al. A multivariate analysis of risk factors for the air-trapping asthmatic phenotype as measured by quantitative CT analysis. Chest 2009, 135:48-56.
139. de Lange E.E., Altes T.A., Patrie J.T., et al. Evaluation of asthma with hyperpolarized helium-3 MRI: correlation with clinical severity and spirometry. Chest 2006, 130:1055-1062.